<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02951156</url>
  </required_header>
  <id_info>
    <org_study_id>B9991011</org_study_id>
    <secondary_id>2016-002904-15</secondary_id>
    <nct_id>NCT02951156</nct_id>
  </id_info>
  <brief_title>Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)</brief_title>
  <acronym>Javelin DLBCL</acronym>
  <official_title>Phase 1b/Phase 3 Multicenter Study Of Avelumab (msb0010718c) In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, Cd20 Antagonist And/or Conventional Chemotherapy In Patients With Relapsed Or Refractory Diffuse Large B-cell Lymphoma (Dlbcl) Javelin Dlbcl</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EMD Serono</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase
      1b followed by Phase 3), parallel-arm study of avelumab in combination with various agents
      for the treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The target study population of this Phase 1b/3 registrational study is patients with R/R
      DLBCL who have completed at least 2 (but not more than 4) lines of prior rituximab-containing
      multi-agent chemotherapy, and/or in whom autologous stem cell transplant (ASCT) has failed,
      or who are not candidates for ASCT or who are not eligible for intensive chemotherapy.
      Patients who are ineligible for intensive second line chemotherapy must have received at
      least one prior rituximab-containing combination chemotherapy regimen. The study will assess
      the safety, efficacy, pharmacokinetics (PK), immunogenicity of the 3 avelumab-based
      combination regimens tested, and collect patient reported outcome (PRO) data.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 16, 2016</start_date>
  <completion_date type="Anticipated">May 29, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1b: Dose Limiting Toxicity (DLT)</measure>
    <time_frame>The first cycle (28 days) observation for 4-weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1b: Objective Response (OR)</measure>
    <time_frame>From date of randomization until the date of first documented disease progression or date of death due to any cause, whichever comes first assessed up to 120 months</time_frame>
    <description>Per Lugano Response Classification Criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 3: Progression Free Survival (PFS)</measure>
    <time_frame>From the date of randomization until the date of the first documentation of objective Progressive Disease (PD) or date of death due to any cause, whichever occurs first assessed up to 120 months.</time_frame>
    <description>Determined by Blinded Independent Central Review (BICR) per Lugano Response Classification Criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Duration of Response (DR)</measure>
    <time_frame>From the date of first documentation of objective response (CR or PR) to the date of first documentation of objective progression of disease (PD) or death due to any cause assessed up to 120 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Time to Tumor Response (TTR)</measure>
    <time_frame>From the date of randomization to the first documentation of objective response (CR or PR) assessed up to 120 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Disease Control (DC)</measure>
    <time_frame>From the date of randomization to the date of PD, death or start of new anti-cancer therapy, whichever comes first, assessed up to 120 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Progression-Free Survival (PFS)</measure>
    <time_frame>From the date of randomization until the date of the first documentation of PD or death due to any cause, whichever occurs first, assessed up to 120 months</time_frame>
    <description>By Investigator assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Overall Survival (OS)</measure>
    <time_frame>From the date of randomization to the date of death due to any cause, whichever comes first assessed up to 120 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Minimal Residual Disease (MRD) burden</measure>
    <time_frame>From the date of randomization, 3, 6, 9, 12 months and after 12-months, every 6 months until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 120 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3: Overall Survival (OS)</measure>
    <time_frame>From the date of randomization to the date of death due to any cause, whichever comes first assessed up to 120 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3: Progression Free Survival (PFS)</measure>
    <time_frame>From the date of randomization until the date of the first documentation of PD or death due to any cause, whichever occurs first, assessed up to 120 months</time_frame>
    <description>By Investigator assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3: Objective Response (OR)</measure>
    <time_frame>From date of randomization until the date of first documented disease progression or date of death due to any cause, whichever comes first assessed up to 120 months</time_frame>
    <description>BICR and Investigator assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3: Time to Tumor Response (TTR)</measure>
    <time_frame>From the date of randomization to the first documentation of objective response (CR or PR) assessed up to 120 months</time_frame>
    <description>BICR and Investigator assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3: Duration of Response (DR)</measure>
    <time_frame>From the date of first documentation of objective response (CR or PR) to the date of first documentation of objective progression of disease (PD) or death due to any cause assessed up to 120 months</time_frame>
    <description>BICR and Investigator assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3: Disease Control (DC).</measure>
    <time_frame>From the date of randomization to the date of PD, death or start of new anti-cancer therapy, whichever comes first, assessed up to 120 months</time_frame>
    <description>BICR and Investigator assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3:Change from baseline in Brief Fatigue Inventory (BFI) questionnaire</measure>
    <time_frame>The first day of the first study visit and every 28 days thereafter up to 120 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3: Minimal residual disease (MRD) burden</measure>
    <time_frame>From the date of randomization, 3, 6, 9, 12 months and after 12-months, every 6 months until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 120 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Phase 1b: AUC(0-Ï„) [Area under the serum concentration time profile from time zero to the next dose (after single dose)]</measure>
    <time_frame>avelumab: pre-dose and 1 hour (at the end of infusion) following the first dose on Day 2 of Cycle 1, then on Day 8 and 16 of Cycle 1. Pre-dose samples will also be collected on Day 1 of Cycles 4 and 6.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Anti-Drug Antibody (ADA); neutralizing antibodies (Nab) against avelumab</measure>
    <time_frame>Pre-dose on Day 2 of Cycle 1 and pre-dose on Day 1 of Cycles 4 and 6. Additional samples for ADAs will be collected at 30 days after the end of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: PD L1 expression levels in tumor cells and cells of the tumor microenvironment at baseline</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3: Change from baseline in the NCCN-FACT FLymSI-18 questionnaire</measure>
    <time_frame>First day of the first visit, and every 28 days. through the 90-day follow-up visit after EOT.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3: Change from baseline in the EQ-5D-5L questionnaire</measure>
    <time_frame>First day of the first visit, and every 7 days. through the 90-day follow-up visit after EOT.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3: AUC(0-Ï„) [Area under the serum concentration time profile from time zero to the next dose (after single dose)</measure>
    <time_frame>for avelumab: pre-dose and 1 hour (at the end of infusion) then on Day 8 and 16 of Cycle 1. Pre-dose samples will also be collected on Day 1 of Cycles 4 and 6.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3: Cmax [(Maximum observed serum concentration (after single dose)]</measure>
    <time_frame>for avelumab: pre-dose and 1 hour (at the end of infusion) following the first dose of avelumab on Day 2 of Cycle 1, then on Day 8 and 16 of Cycle 1. Pre-dose samples will also be collected on Day 1 of Cycles 4 and 6. ]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3: PD-L1 expression levels in tumor cells and cells of the tumor microenvironment at baseline</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Anti-Drug Antibody (ADA); neutralizing antibodies (Nab) against rituximab</measure>
    <time_frame>Pre-dose on Day 1 of Cycle 1 and pre-dose on Day 1 of Cycles 4 and 6. Additional samples for ADAs will be collected at 30 days after the end of therapy for rituximab</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Anti-Drug Antibody (ADA); neutralizing antibodies (Nab) against utomilumab</measure>
    <time_frame>Pre-dose on Day 2 of Cycle 1 and pre-dose on Day 1 of Cycles 4 and 6. Additional samples for ADAs will be collected 30 days after the end of therapy for utomilumab.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3: Anti-Drug Antibody (ADA); neutralizing antibodies (Nab) against avelumab</measure>
    <time_frame>Pre-dose on Day 2 of Cycle 1 and pre-dose on Day 1 of Cycles 4 and 6. Additional samples for ADAs will be collected at 30 days after the end of therapy.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3: Anti-Drug Antibody (ADA); neutralizing antibodies (Nab) against rituximab</measure>
    <time_frame>Pre-dose on Day 1 of Cycle 1 and pre-dose on Day 1 of Cycles 4 and 6. Additional samples for ADAs will be collected at 30 days after the end of therapy for rituximab</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3: Anti-Drug Antibody (ADA); neutralizing antibodies (Nab) against utomilumab</measure>
    <time_frame>Pre-dose on Day 2 of Cycle 1 and pre-dose on Day 1 of Cycles 4 and 6. Additional samples for ADAs will be collected 30 days after the end of therapy for utomilumab</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: AUC(0-t) [Area under the serum concentration time profile from time zero to the time of the last quantifiable concentration (C last) (after single dose)</measure>
    <time_frame>rituximab: pre-dose and at the end of infusion on Day 1 of Cycle 1, then on Days 7, 15 and 22 of Cycle 1. Pre-dose samples will also be collected on Day 1 of Cycles 4 and 6.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: AUC(0-t) Area under the serum concentration time profile from time zero to the time of the last quantifiable concentration (C last) [after single dose]</measure>
    <time_frame>utomilumab: pre-dose, and 1 hour (at the end of infusion) following the first dose on Day 2 of the first cycle in the study, and then on Day 16 of Cycle 1. Pre-dose samples will also be collected on Day 1 of Cycles 4 and 6.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: AUC(0-t) Area under the plasma concentration time profile from time zero to the time of the last quantifiable concentration (C last) [after single dose and steady state]</measure>
    <time_frame>azacitidine: pre-dose, 0.5, 1, 2, and 4 hours on Day 1 and 5 of Cycle 1. Samples pre-dose and at 0.5 hour will also be collected on Day 1 of Cycles 4 and 6.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: AUC(0-t) Area under the plasma concentration time profile from time zero to the time of the last quantifiable concentration (C last) [after single dose]</measure>
    <time_frame>bendamustine (and M3 metabolite) pre-dose and at 1 hour (at the end of infusion), 2, and 4 hours following the first dose in the first cycle. Samples at pre-dose and 1 hour will also be collected following the first dose of Cycles 4 and 6.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Maximum observed serum concentration (after single dose)</measure>
    <time_frame>for avelumab: pre-dose and 1 hour (at the end of infusion) following the first dose on the Day 2 of Cycle 1, and additional samples will be collected on Day 8 and 16 of Cycle 1. Pre-dose samples will also be collected on Day 1 of Cycles 4 and 6.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Maximum observed serum concentration (after single dose)</measure>
    <time_frame>rituximab: pre-dose and at the end of infusion on Day 1 in Cycle 1, and then on Days 7, 15 and 22 of Cycle 1. Pre-dose samples will also be collected on Day 1 of Cycles 4 and 6.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Maximum observed serum concentration (after single dose)</measure>
    <time_frame>utomilumab: pre-dose, and 1 hour (at the end of infusion) following the first dose on Day 2 of the first cycle in the study, and then on Day 16 of Cycle 1. Pre-dose samples will also be collected on Day 1 of Cycles 4 and 6.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Maximum observed plasma concentration (after single dose and at steady state)</measure>
    <time_frame>azacitidine: pre-dose, 0.5, 1, 2, and 4 hours on Day 1 and 5 of Cycle 1. Samples pre-dose and at 0.5 hour will also be collected on Day 1 of Cycles 4 and 6.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Maximum observed plasma concentration (after single dose and at steady state)</measure>
    <time_frame>bendamustine (and M3 metabolite) pre-dose and at 1 hour (at the end of infusion), 2, and 4 hours following the first dose in the first cycle. Samples at pre-dose and 1 hour will also be collected following the first dose of Cycles 4 and 6.</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">304</enrollment>
  <condition>Diffuse Large B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Phase 1b Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>avelumab/utomilumab/rituximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>avelumab/utomilumab/azacitidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>avelumab/rituximab/bendamustine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 3 Arm D (selected from Phase 1b)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Selected regimen from Phase 1b component which may be i) avelumab/utomilumab/rituximab OR ii) avelumab/rituximab/azacitidine OR iii) avelumab/rituximab/bendamustine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 3 Arm E</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Investigator's Choice of either rituximab/bendamustine or rituximab/gemcitabine/oxaliplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>Investigational fully human anti-PD-L1 monoclonal antibody</description>
    <arm_group_label>Phase 1b Arm A</arm_group_label>
    <arm_group_label>Phase 1b Arm B</arm_group_label>
    <arm_group_label>Phase 1b Arm C</arm_group_label>
    <arm_group_label>Phase 3 Arm D (selected from Phase 1b)</arm_group_label>
    <other_name>MSB0010718C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Utomilumab</intervention_name>
    <description>Investigational, fully human IgG2 CD 137/4-1BB agonist</description>
    <arm_group_label>Phase 1b Arm A</arm_group_label>
    <arm_group_label>Phase 1b Arm B</arm_group_label>
    <arm_group_label>Phase 3 Arm D (selected from Phase 1b)</arm_group_label>
    <other_name>PF-05082566</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>CD20-directed cytolytic antibody</description>
    <arm_group_label>Phase 1b Arm A</arm_group_label>
    <arm_group_label>Phase 1b Arm C</arm_group_label>
    <arm_group_label>Phase 3 Arm D (selected from Phase 1b)</arm_group_label>
    <arm_group_label>Phase 3 Arm E</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Antimetabolite antineoplastic agent and demethylation agent.</description>
    <arm_group_label>Phase 1b Arm B</arm_group_label>
    <arm_group_label>Phase 3 Arm D (selected from Phase 1b)</arm_group_label>
    <other_name>Vidaza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Alkylating drug</description>
    <arm_group_label>Phase 1b Arm C</arm_group_label>
    <arm_group_label>Phase 3 Arm D (selected from Phase 1b)</arm_group_label>
    <arm_group_label>Phase 3 Arm E</arm_group_label>
    <other_name>Treanda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Nucleoside analogue</description>
    <arm_group_label>Phase 3 Arm E</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Platinum-based drug</description>
    <arm_group_label>Phase 3 Arm E</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

        -Any of the following as defined by the WHO, 2016 lymphoid neoplasm classifications and
        histologically confirmed:

          -  Diffuse large B-cell lymphoma (DLBCL), Not Otherwise Specified (NOS): Germinal center
             B-cell type (GCB), Activated B-cell type (ABC)

          -  High-grade B-cell lymphoma (HGBCL) NOS

          -  HGBCL with MYC and BCL2 and/or BCL6 rearrangements

          -  T-cell histocyte-rich large B-cell lymphoma

          -  EBV+ DLBCL, NOS

          -  HHV8+ DLBCL, NOS

        Relapsed or refractory disease following at least 2 lines (and a maximum of 4 lines) of
        prior rituximab containing multi-agent chemotherapy which may include an autologous stem
        cell transplantation unless patients are not considered suitable for intensive second-line
        chemotherapy or autologous stem cell transplantation. Patients who are ineligible for
        intensive second line chemotherapy,must have received at least one prior
        rituximab-containing combination chemotherapy regimen. Patients who are ineligible for
        intensive second line chemotherapy, must have received at least one prior
        rituximab-containing combination chemotherapy regimen.

          -  Baseline measurable disease with at least 1 bi dimensional lesion with longest
             diameter (LDi) &gt;1.5cm on CT scan which is FDG avid on PET scan.

          -  A biopsy (archived or Screening/recent) will be collected at Screening.

          -  At least 18years of age (or â‰¥20 years in Japan).

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1.

        Key Exclusion Criteria:

          -  Active central nervous system (CNS) lymphoma.

          -  Prior organ transplantation including prior allogeneic SCT.

          -  Prior therapy with an anti PD 1, anti PD L1, anti PD L2, anti CD137, or anti cytotoxic
             T lymphocyte associated antigen 4 (CTLA 4) antibody (including ipilimumab,
             tremelimumab or any other antibody, or drug specifically targeting T cell co
             stimulatory or immune checkpoint pathways).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope Investigational Drug Services</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Norton Diagnostic Center - Dupont</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Norton Women's and Children's Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tulane Medial Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tulane Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Shore Hematology Oncology Associates</name>
      <address>
        <city>East Setauket</city>
        <state>New York</state>
        <zip>11733</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nuclear Medicine Department</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pharmacy Department</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Radiology Department</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. George Hospital</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Pharmacy Monash Health</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Monash Health</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Monash Imaging</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cancer Clinical Trials Centre, Austin Health, Level 4</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Department of Pharmacy</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nuclear Medicine</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Radiology Department</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan Brugge-Oostende AV</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Kralovske Vinohrady</name>
      <address>
        <city>Praha 10</city>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Region Hovedstadens Apotek</name>
      <address>
        <city>KÃ¸benhavn Ã˜</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>KÃ¸benhavn Ã˜</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHD VendÃ©e</name>
      <address>
        <city>La Roche-Sur-Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Nantes - HÃ´tel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Rennes - HÃ´pital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Scientifico Romagnolo per Studio e Cura di Tumori (IRST)</name>
      <address>
        <city>Meldola</city>
        <state>FC</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRST</name>
      <address>
        <city>Meldola</city>
        <state>FC</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Instituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Farmacia Studi Clinici</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center Clinical Reseach Pharmacy</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center Clinical Trial Pharmacy</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center, Hematology</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Radiologie &amp; Nucleaire Geneeskunde</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Apotheek Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii Ziemi Lubelskiej im Sw. Jana z Dukli</name>
      <address>
        <city>Lublin</city>
        <state>Lubelskie</state>
        <zip>20-090</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii Ziemi Lubelskiej im. Sw. Jana z Dukli</name>
      <address>
        <city>Lublin</city>
        <state>Lubelskie</state>
        <zip>20-090</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Malopolskie Centrum Medyczne S.C.</name>
      <address>
        <city>Krakow</city>
        <state>Malopolskie</state>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nzoz McD Voxel Osrodek Pet-Tk-Nmr</name>
      <address>
        <city>Krakow</city>
        <zip>30-006</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instytut Hematologii i Transfuzjologii</name>
      <address>
        <city>Warszawa</city>
        <zip>00-791</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instytut Hematologii i Transfuzjologii</name>
      <address>
        <city>Warszawa</city>
        <zip>02-776</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NU-MED Centrum Diagnostyki i Terapii Onkologicznej Zamosc Sp. z o.o.</name>
      <address>
        <city>Zamosc</city>
        <zip>22-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IDI-Unitat PET - Hospital Universitari de Bellvitge</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut CatalÃ  d'Oncologia de l'Hospitalet</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Cristina</name>
      <address>
        <city>Badajoz</city>
        <zip>06006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Quiron salud Barcelona - Diagnostico Imagen</name>
      <address>
        <city>Barcelona</city>
        <zip>08023</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CETIR, Centre Medic S.L</name>
      <address>
        <city>Barcelona</city>
        <zip>08029</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital ClÃ­nic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcantara</name>
      <address>
        <city>Caceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcantara</name>
      <address>
        <city>CÃ¡ceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia</name>
      <address>
        <city>CÃ³rdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina SofÃ­a</name>
      <address>
        <city>CÃ³rdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Jimenez DÃ­az</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario FundaciÃ³n JimÃ©nez DÃ­az</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de InvestigaciÃ³n Medicina Especializada Sanitaria (CIMES)</name>
      <address>
        <city>MÃ¡laga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>MÃ¡laga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>APL</name>
      <address>
        <city>Stockholm</city>
        <zip>171 64</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Norrlands Universitetssjukhus</name>
      <address>
        <city>UmeÃ¥</city>
        <zip>90185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sjukhusapoteket, Umea</name>
      <address>
        <city>UmeÃ¥</city>
        <zip>907 37</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS FT</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Christie Pathology Partnership</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B9991011&amp;StudyName=Phase+1b%2Fphase+3+Multicenter+Study+Of+Avelumab+%28msb0010718c%29+In+Combination+Regimens+That+Include+An+Immune+Agonist%2C+Epigenetic+Modulator%2C+Cd20+Agonist+And%2For+Conventional+Chemotherapy+In+Patients+With+Relapsed+Or+Refractory+Diffuse+Large+B+Cell+Lymphoma+%28dlbcl%29</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B9991011&amp;StudyName=Phase+1b%2Fphase+3+Multicenter+Study+Of+Avelumab+%28msb0010718c%29+In+Combination+Regimens+That+Include+An+Immune+Agonist%2C+Epigenetic+Modulator%2C+Cd20+Antagonist+And%2For+Conventional+Chemotherapy+In+Patients+With+Relapsed+Or+Refractory+Diffuse+Large+B-cell+Lymphoma+%28dlbcl%29+Javelin+Dlbcl</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2016</study_first_submitted>
  <study_first_submitted_qc>October 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2016</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

